Understanding how chemotherapy affects immune response in lung cancer treatment
Official title: Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer
Funded at University of Louisville · NIH-11055285 · Data updated 2026-11-12
This study is looking at how the chemotherapy drug cisplatin affects the immune system in people with non-small cell lung cancer, to find out how it might make immunotherapy less effective, and to discover better ways to boost treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $353,044 |
| NIH project number | 5R01CA272772-03 |
| Project ID | NIH-11055285 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing or considering chemotherapy treatment.
✕Less likely to help
Patients with other types of lung cancer or those who are not receiving chemotherapy may not benefit from this research.
What this research studies
This research investigates the effects of cisplatin, a common chemotherapy drug, on the immune response in patients with non-small cell lung cancer (NSCLC). It aims to understand how cisplatin may create an environment that suppresses the effectiveness of immunotherapy, specifically targeting the PD-1 pathway. By studying the interactions between chemotherapy and immune cells, the research seeks to identify new strategies to enhance the efficacy of immunotherapy in lung cancer patients. Patients may be involved in trials that explore these mechanisms and potential new treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance the effectiveness of immunotherapy for lung cancer patients.
How similar studies have gone: Previous research has shown that understanding the tumor microenvironment can lead to significant advancements in cancer treatment, suggesting potential success for this approach.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Yaddanapudi, Kavitha — University of Louisville
- Study coordinator: Yaddanapudi, Kavitha
Related research
Other NIH-funded projects on the same topics.
-
Stopping chemotherapy from weakening immunotherapy in non-small cell lung cancer
This project looks at whether common chemotherapy makes lung tumors release substances that turn off immune cells and whether blocking that process could help immunotherapy work better for people with non-small cell lung cancer.
-
Identifying why small cell lung cancer becomes resistant to chemotherapy
This study is looking into why small cell lung cancer often doesn't respond to chemotherapy, hoping to find new ways to treat it better for patients who are facing this tough disease.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.